Hikma Pharmaceuticals PLC (LON:HIK)
1,585.00
-9.00 (-0.56%)
Jul 31, 2026, 5:13 PM GMT
Hikma Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Hikma Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of 1,861p. The average 1-year stock price forecast is 17.43% higher than the current stock price, while the lowest is 1,336p (-15.69%) and the highest is 2,634p (+66.21%).
Price Target: 1,861p (+17.43%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Hikma Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Initiates 1,700p | Buy | Initiates | 1,700p | +7.26% | Jul 16, 2026 |
| Barclays | Barclays | Sell Maintains 1,350p | Sell | Maintains | 1,350p | -14.83% | Jun 23, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Reiterates 1,950p | Buy | Reiterates | 1,950p | +23.03% | Jun 22, 2026 |
| Jefferies | Jefferies | Buy Reiterates 1,850p → 1,870p | Buy | Reiterates | 1,850p → 1,870p | +17.98% | May 5, 2026 |
| Berenberg Bank | Berenberg Bank | Buy Reiterates 1,800p | Buy | Reiterates | 1,800p | +13.56% | Apr 28, 2026 |
Financial Forecast
Revenue This Year
3.46B
from 3.35B
Increased by 3.29%
Revenue Next Year
3.61B
from 3.46B
Increased by 4.43%
EPS This Year
2.22
from 2.26
Decreased by -1.86%
EPS Next Year
2.45
from 2.22
Increased by 10.34%
EPS and Forward PE are based on non-GAAP adjusted numbers.